EP3866768A4 - USING REBOXETINE TO TREAT NARCOLEPSY - Google Patents

USING REBOXETINE TO TREAT NARCOLEPSY Download PDF

Info

Publication number
EP3866768A4
EP3866768A4 EP19874099.5A EP19874099A EP3866768A4 EP 3866768 A4 EP3866768 A4 EP 3866768A4 EP 19874099 A EP19874099 A EP 19874099A EP 3866768 A4 EP3866768 A4 EP 3866768A4
Authority
EP
European Patent Office
Prior art keywords
reboxetine
treat narcolepsy
narcolepsy
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19874099.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3866768A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP3866768A1 publication Critical patent/EP3866768A1/en
Publication of EP3866768A4 publication Critical patent/EP3866768A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
EP19874099.5A 2018-10-15 2019-10-14 USING REBOXETINE TO TREAT NARCOLEPSY Pending EP3866768A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (2)

Publication Number Publication Date
EP3866768A1 EP3866768A1 (en) 2021-08-25
EP3866768A4 true EP3866768A4 (en) 2022-01-05

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19874099.5A Pending EP3866768A4 (en) 2018-10-15 2019-10-14 USING REBOXETINE TO TREAT NARCOLEPSY

Country Status (16)

Country Link
EP (1) EP3866768A4 (es)
JP (1) JP2022504975A (es)
KR (1) KR20210071046A (es)
CN (1) CN112888430A (es)
AU (2) AU2019361915A1 (es)
BR (1) BR112021007019A2 (es)
CA (1) CA3115983A1 (es)
CL (1) CL2021000924A1 (es)
CO (1) CO2021004681A2 (es)
CR (1) CR20210514A (es)
EC (1) ECSP21031200A (es)
IL (1) IL282311A (es)
MX (1) MX2021004207A (es)
PE (1) PE20211199A1 (es)
SG (1) SG11202103588WA (es)
WO (1) WO2020081461A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (ko) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
KR102192554B1 (ko) * 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARCIA-BORREGUERO D ET AL: "Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP (ROCHESTER), vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), & 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, pages A323 - A324, XP009531711, ISSN: 0161-8105 *
O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 *
SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 *

Also Published As

Publication number Publication date
PE20211199A1 (es) 2021-07-01
CR20210514A (es) 2021-11-12
CL2021000924A1 (es) 2021-09-03
SG11202103588WA (en) 2021-05-28
EP3866768A1 (en) 2021-08-25
WO2020081461A1 (en) 2020-04-23
AU2023200917A1 (en) 2023-03-23
IL282311A (en) 2021-05-31
AU2019361915A1 (en) 2021-05-13
ECSP21031200A (es) 2021-05-31
CA3115983A1 (en) 2020-04-23
MX2021004207A (es) 2021-08-11
JP2022504975A (ja) 2022-01-13
CN112888430A (zh) 2021-06-01
KR20210071046A (ko) 2021-06-15
CO2021004681A2 (es) 2021-06-21
BR112021007019A2 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
EP3612551A4 (en) VARIANTS OF CPF1 (CAS12A) WITH MODIFIED PAM SPECIFICITY
EP3313404A4 (en) THERAPEUTIC COMPOSITIONS, ASSOCIATIONS AND METHODS OF USE
EP3426250A4 (en) TREATMENT PROCEDURE
EP3294289A4 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
EP3256113A4 (en) Treatment of hypoparathyroidism
GB201804514D0 (en) Treatment of pyroptosis
IL282311A (en) Raboxetine for the treatment of narcolepsy
EP3370726A4 (en) USE OF TLR8 AGONISTS FOR CANCER TREATMENT
EP3536320A4 (en) APPLICATION OF A HEDGEHOG SIGNALWAY INHIBITOR FOR TREATING FIBROTIC DISEASES
EP3359258A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROTIC SKIN DISEASES
EP3902524A4 (en) TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR
EP3833372A4 (en) TREATMENT OF EGFR MUTANT CANCER
EP3675871A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF FIBROTIC DISEASES
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
EP3609500A4 (en) ADIPOCYTE TREATMENT
EP3752466A4 (en) TREATMENT OF WATER CONTAINING CYANOTOXIN
EP3661507A4 (en) USE OF GABOXADOL TO TREAT NARCOLEPSIA
GB201804515D0 (en) Treatment of necroptosis
EP3829619A4 (en) TREATMENT OF MUCOPOLYSACCHARIDOSE IVA
EP3600285A4 (en) TOPICAL COMPOSITIONS AND METHODS OF TREATMENT
EP3976085A4 (en) USING PRG4 TO TREAT CANCER
EP3721889A4 (en) USE OF DEBUTYRIBACTER INTESTINI
EP3878454A4 (en) USE OF 3-O-SULFAMATE-16,16-DIMETHYL-D-HOMOEQUILENIN IN THE TREATMENT OF ONCOLOGICAL DISEASES
ZA202105399B (en) Use of spiropidion
IL282869A (en) Use of tibozenib to treat patients with resistant cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210506

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20211207

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20211201BHEP

Ipc: A61K 31/5375 20060101ALI20211201BHEP

Ipc: A61K 9/22 20060101AFI20211201BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060016

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230927